Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

(2023) Karim Fizazi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

(2022) Fred Saad et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.

(2022) Kim N. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

(2022) Matthew R Smith et al.   LANCET ONCOLOGY

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes

(2022) Joshua J. Gruber et al.   Nature Cancer

Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians

(2021) Axel S. Merseburger et al.   EUROPEAN UROLOGY

Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2

(2021) Kim A. Reiss et al.   JOURNAL OF CLINICAL ONCOLOGY

Prostate cancer and PARP inhibitors: progress and challenges

(2021) Diego Teyssonneau et al.   Journal of Hematology & Oncology

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

(2021) P. Grivas et al.   BMC CANCER

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

(2021) Johann S de Bono et al.   LANCET ONCOLOGY

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study

(2020) Wassim Abida et al.   CLINICAL CANCER RESEARCH

Olaparib for Metastatic Castration-Resistant Prostate Cancer

(2020) Johann de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

(2020) Wassim Abida et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic correlates of clinical outcome in advanced prostate cancer

(2019) Wassim Abida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines

(2019) Cynthia L. Neben et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors

(2019) Graziela Zibetti Dal Molin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

(2018) Travis A. Clark et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

(2018) Anis A. Hamid et al.   EUROPEAN UROLOGY

In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib

(2016) Alex McCormick et al.   XENOBIOTICA

Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

(2015) A. M. Aparicio et al.   CLINICAL CANCER RESEARCH

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

(2015) Roberta Ferraldeschi et al.   EUROPEAN UROLOGY

Prediction of Clinical Drug–Drug Interactions of Veliparib (ABT-888) with Human Renal Transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)

(2013) Ryota Kikuchi et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY